BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36575406)

  • 1. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
    Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
    BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of
    Honda N; Tagashira Y; Kawai S; Kobayashi T; Yamamoto M; Shimada K; Yokogawa N
    Scand J Rheumatol; 2021 Sep; 50(5):365-371. PubMed ID: 33749507
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
    Dilworth TJ; Ibrahim OM; Mercier RC
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
    Tritle BJ; Hejazi AA; Timbrook TT
    Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
    Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
    Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
    BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab.
    Park JW; Curtis JR; Choi SR; Kim MJ; Ha YJ; Kang EH; Lee YJ; Lee EB
    Arthritis Rheumatol; 2023 Nov; 75(11):2036-2044. PubMed ID: 37096489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sub-therapeutic trimethoprim and sulfamethoxazole plasma concentrations during continuous venovenous hemofiltration in a patient with COVID-19 and pulmonary
    le Noble JLML; Foudraine N; van der Elst KCM; Bouwman S
    Int J Clin Pharmacol Ther; 2023 Nov; 61(11):525-530. PubMed ID: 37489071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
    Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
    Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
    Geerlinks AV; Campigotto A; Science M; Gupta S
    Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose vsĀ Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia inĀ Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.